Source-grounded facts extracted from Chemomab Therapeutics Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Donald Marvin resigned as Chief Financial Officer at Chemomab Therapeutics Ltd..
“the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.”
Dale Pfost departed as Chief Executive Officer at Chemomab Therapeutics Ltd..
“In connection with his replacement as Chief Executive Officer, on June 1, 2023, Dr. Dale Pfost agreed to step down from his position on the Board, including in his capacity as Chairman of the Board, effective as of the same date.”
Sigal Fattal was appointed as Chief Financial Officer at Chemomab Therapeutics Ltd..
“the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.”
Adi Mor was appointed as Chief Executive Officer at Chemomab Therapeutics Ltd..
“appointed Dr. Adi Mor, co-founder of the Company, a current class III member of the Board and the Company's Chief Scientific Officer, as Chief Executive Officer of the Company to replace Dr. Dale Pfost, effective as of the same date.”
Chemomab Therapeutics Ltd. reported first quarter ended March 31, 2023 results: net income $8.8 million, EPS approximately $0.04 per basic and diluted ordinary share.
“Net loss was $8.8 million, or a net loss of approximately $0.04 per basic and diluted ordinary share for the first quarter of 2023”
Chemomab Therapeutics Ltd. reported financial results for fiscal year ended December 31, 2022.
“Chemomab Therapeutics Ltd. (“we,” “us,” “our,” or the “Company”) is disclosing its consolidated audited financial statements for the fiscal year ended December 31, 2022”
Dr. Matthew B. Frankel was appointed as Chief Medical Officer & VP, Drug Development at Chemomab Therapeutics Ltd..
“On November 14, 2022, Chemomab Therapeutics Ltd. (the “Company”) announced the appointment of Dr. Matthew B. Frankel as Chief Medical Officer & VP, Drug Development of the Company.”
Jill M. Quigley was appointed as Director at Chemomab Therapeutics Ltd..
“appointed Jill M. Quigley to the Board and the audit committee of the Board (the “Audit Committee”), effective immediately.”
Joel Maryles departed as Class I Director at Chemomab Therapeutics Ltd..
“On May 31, 2022, Joel Maryles, a member of the Board of Directors (the “Board”) of Chemomab Therapeutics Ltd. (the “Company”), notified the Company that he will not stand for re-election at the Company’s 2022 Annual General Meeting of shareholders, to be held on June 7, 2022, and, accordingly, Mr. Maryles’ term as a Class I director will expire at the 2022 Annual General Meeting.”
Dale Pfost was appointed as Chairman of the Board at Chemomab Therapeutics Ltd..
“the nominating and governance committee and the Board each approved and recommended that the shareholders approve the appointment of Dr. Pfost as chairman of the Board.”
Stephen Squinto resigned as Chairman of the Board at Chemomab Therapeutics Ltd..
“On December 12, 2021, the Company and Mr. Squinto mutually agreed that Mr. Squinto’s resignation as the chairman of the Board will enter into effect on December 19, 2021.”
Dr. Arnon Aharon resigned as Chief Medical Officer at Chemomab Therapeutics Ltd..
“On November 29, 2021, Dr. Arnon Aharon notified Chemomab Therapeutics Ltd. (the “Company”) of his resignation as its Chief Medical Officer, which will enter into effect on February 1, 2022.”
Donald Marvin was appointed as Chief Financial Officer, Executive Vice President and Chief Operating Officer at Chemomab Therapeutics Ltd..
“it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.”
Donald Marvin was appointed as Chief Financial Officer, Executive Vice President and Chief Operating Officer at Chemomab Therapeutics Ltd..
“On November 8, 2021, the Company issued a press release announcing that, on November 8, 2021, it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.”
Sigal Fattal departed as Interim Chief Financial Officer at Chemomab Therapeutics Ltd..
“On November 8, 2021, Chemomab Therapeutics Ltd. (the “Company”) and Ms. Sigal Fattal mutually agreed to conclude Ms. Fattal’s engagement as Interim Chief Financial Officer of the Company and its wholly-owned subsidiary Chemomab Ltd. (the “Subsidiary”).”
Adi Mor changed role as Chief Scientific Officer at Chemomab Therapeutics Ltd..
“Dr. Pfost will replace Dr. Adi Mor, who will step down from her role as Chief Executive Officer, effective as of the appointment of Dr. Pfost, and who will continue to be employed by the Company as Chief Scientific Officer where she will oversee scientific strategy and R&D operations.”
Dale Pfost was appointed as Chief Executive Officer at Chemomab Therapeutics Ltd..
“On September 2, 2021, Chemomab Therapeutics Ltd. (the “Company”) announced the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.